I've posted before but rare but anyways to remind u. I'm...

I've posted before but rare but anyways to remind u. I'm pharmacy and medicine background.

anyways did PRR publish a proper journal article of some sort on this particular study? I'm having trouble finding it on medline. I'm referring to the ACTUAL paper not a 1 slide thing in the investor presentation. HOWEVER!

Based on the one slider they picked really end stage overian cancer patients.

• rising CA125 levels at least 25% over baseline within 28 days
• multiple courses of chemotherapy/ radiotherapy

I can tell you that CA125 rises like a mother@#$%er when patients become resistant to treatment or if the treatment isn't taking. I know this on a personal level as well from a family member.

The fact that 4 out of 21 patient's responded and there was 127 day progression free survival and 219 day survival is very promising. This is because if administered to patients whom overian cancer isn't as advanced would as the ones recruited in this study we would get a much better results, but we shall see with the phase IIb and phase III trials.

As for toxicity its not a problem and likely never will be as your using the patients own immune cells, probably likely to just get flu like symptoms.

Anyways if anyone has access to the actual paper of this trial I'd really like to take a look at it.

The main concern from a health care budget point of view is cost. Does anyone know how much a course of treatment is going to be? because the govt/PBS guys ain't going to cover it just to prolong life for 4 months in 20% of patients if it costs say $100,000 per course. Sorry I know it sounds cruel but that's how it works.

For those of you that know one of the PBS requirement as one stage to enable a patient to get PLAVIX® (clopidogrel bisulfate) was that they had to have had 2 heart attacks.